Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer’s Disease in Persons with Down Syndrome
News
Immunome Reports First Quarter 2021 Financial Results
– IMM-BCP-01: Selected antibody cocktail demonstrating neutralization of CDC SARS-CoV-2 “variants of concern” in preclinical testing, progressing towards IND filing –
– IMM-ONC-01: Advanced proprietary antibody against IL-38, a novel innate immune checkpoint, into IND-enabling studies –
– Dennis Giesing, Ph.D. appointed as Chief Development Officer and Corleen Roche appointed as Chief Financial Officer –
– Raised $27 million in gross proceeds in a private placement –
Venatorx Pharmaceuticals’ Novel Antibiotic Pipeline Addresses the Next Pandemic: Superbugs
Company to Watch – Venatorx Pharmaceuticals
3D Systems Announces Two Strategic Growth Acquisitions
– Acquisition of Allevi, Inc. to expand regenerative medicine initiative by accelerating growth in medical and pharmaceutical research laboratories
– Acquisition of German software firm, Additive Works GmbH to expand simulation capabilities for rapid optimization of industrial-scale 3D printing processes
Wellsheet Appoints Healthcare Veteran Ryan Sadlo to Help Health Systems Modernize EHR Systems to Address Physician Burnout
New Vice President of Growth to Accelerate Commercial Operations in the Public and Private Sector
Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
– Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary, non-overlapping regions of the SARS-CoV-2 spike protein.
– Efficacious in Syrian hamsters infected with SARS-CoV-2 (USA-WA1/2020) in both prophylactic and treatment schedules.
– Neutralizes South Africa (B.1.351) and UK (B.1.1.7) in live virus testing; Brazil (P.1) and California (B.1.429, also containing B.1.427 mutations) in pseudovirus testing, all of which are CDC-designated “Variants of Concern.”
– Investigational New Drug (IND) Filing planned for late 2Q/early 3Q 2021.
Halo Labs Launches the Aura CL™ for Cell Therapy Product Quality
Aura CL is the first system specifically designed to quantify cell aggregates and ID cell vs non-cell contaminants
Immunome Appoints Corleen Roche as Chief Financial Officer
– Seasoned biopharmaceutical executive with more than 30 years of corporate finance and business strategy experience –
Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder